You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DLBCL

Showing 26 - 50 of 915
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 19, 2023

B Cell Lymphoma Trial in Tel-Aviv (Nivolumab Injection [Opdivo])

Recruiting
  • B Cell Lymphoma
  • Nivolumab Injection [Opdivo]
  • Tel-Aviv, Israel
    Tel-Aviv Sourasky Medicak center / BMT Unit
May 22, 2022

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 15, 2022

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    DLBCL, Lymphoma, B-Cell Trial in Rochester (Polatuzumab vedotin, Rituximab, Cyclophosphamide)

    Recruiting
    • DLBCL
    • Lymphoma, B-Cell
    • Polatuzumab vedotin
    • +4 more
    • Rochester, New York
      University of Rochester
    Jan 6, 2022

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023

    Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

    Not yet recruiting
    • Primary Extranodal Lymphoma
    • DLBCL
    • (no location specified)
    Apr 6, 2022

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

    Not yet recruiting
    • Relapsed or Refractory DLBCL
    • Anti-PD-1 Antibody Plus Chidamide and Rituximab
    • (no location specified)
    Apr 6, 2022

    Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

    Recruiting
    • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
    • With and Without MyD88 and/or CD79B Mutations
    • Evanston, Illinois
    • +6 more
    Dec 12, 2022

    DLBCL, MCL, and FL Patients Undergoing CAR Therapy

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • ClonoSEQ
    • Palo Alto, California
      Stanford Cancer Center
    Apr 19, 2022

    Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

    Recruiting
    • Diffuse Large B-cell Lymphoma(DLBCL)
    • Zanubrutinib + R-CHOP
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 10, 2022

    Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • R-CHOP + acalabrutinib
    • Southampton, Hampshire, United Kingdom
    • +6 more
    Oct 26, 2022

    Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

    Completed
    • Diffuse Large B Cell Lymphoma
    • PrednisoLONE 50 MG
    • Busan, Sue-gu, Korea, Republic of
      Kosin University Gospel Hospital
    Mar 31, 2022

    Diffuse Large B Cell Lymphoma Trial (Venetoclax, Carmustine, Cytarabine)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    May 9, 2023

    Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib plus RCHOP
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 16, 2023

    Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

    Recruiting
    • Diffuse Large B Cell Lymphoma
      • Salvador, Bahia, Brazil
      • +9 more
      Jul 24, 2023

      B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

      Recruiting
      • B-ALL
      • +10 more
      • 131-I Apamistamab
      • CAR T-cell
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Mar 7, 2022

      Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

      Not yet recruiting
      • Mature B-Cell Neoplasm
      • +25 more
      • (no location specified)
      Sep 14, 2022

      Tafasitamab in Combination With Lenalidomide in Patients withR/R

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Tafasitamab Injection
      • Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      May 31, 2023

      Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

      Active, not recruiting
      • Diffuse Large B-cell Lymphoma (DLBCL)
      • L19-IL2 - Ph I
      • +2 more
      • Münster, Germany
        Münster University Hospital
      Apr 19, 2022